Research · Source update
Retatrutide TRIUMPH-1 reports 28.3% average loss at 12 mg
Source context: Read the linked original research or registry entry for study status and limitations.
Eli Lilly published Phase 3 topline results for investigational retatrutide in people with obesity or overweight without diabetes. MyDosePro reviewed the originating organization's statement to identify the reported results and their limitations.
What was tested?
TRIUMPH-1 was a Phase 3 obesity trial of retatrutide, an investigational medicine that activates GIP, GLP-1 and glucagon receptors. Lilly enrolled adults with obesity, or overweight with a related condition, who did not have diabetes. The primary analysis evaluated body-weight change after 80 weeks, not simply the first few months of treatment.
What were the reported results?
In its May 21, 2026 topline announcement, Lilly reported a 28.3% mean weight reduction at the 12 mg dose after 80 weeks, equivalent to about 70.3 pounds on average in that study group. The company said 45.3% at that dose achieved at least 30% weight loss. At 4 mg, average loss was reported as 19.0%. These percentages describe different assigned-dose groups rather than an individualized dose recommendation.
What about longer follow-up?
The company separately described a study extension among participants with starting BMI at least 35. At 104 weeks, it reported up to 30.3% average loss for the specified group. An extension population differs from the full randomized trial, so readers should not treat those results as the expected two-year outcome for everybody.
What remains uncertain?
Retatrutide was investigational when these findings were announced. A sponsor press release is not the same as an FDA approval or a completed independent analysis of the full clinical dataset. Adverse-event rates, discontinuations and protocol differences matter alongside headline efficacy.
Why does this matter?
The findings show why triple-receptor approaches are receiving attention, but patients cannot simply obtain investigational retatrutide as an approved prescription. Compare marketed options using their actual labels and discuss choices with a qualified clinician.
The bottom line
Strong trial findings do not equal FDA approval.
Written and published by MyDosePro as an educational explanation of publicly available evidence. The linked primary source is dated 2026-05-21. We identify trial registrations separately from published results and do not provide individual prescribing advice.
Primary sourceLilly TRIUMPH-1 phase 3 announcement ↗
Source event or update: 2026-05-21. Our interpretation is educational and does not replace medical or insurance advice.